The Proteomics Core will employ cutting-edge proteomics technologies to help address mechanistic questions proposed by the four JHM Udall Center research projects regarding the pathogenesis of Parkinson's disease (PD). The methodologies available through the Proteomics Core provide efficient and sensitive strategies to identify and quantify PD-associated changes in the samples obtained from both disease models and human patients. Thus, we anticipate that proteomic findings generated by the Proteomics Core will help elucidate specific protein-based cellular mechanisms that correlate with PD pathogenesis, identifying novel pathogenic proteins, signaling nodes and protein PTMs with strong association to PD. To this end, the Proteomics Core will provide innovative and traditional mass spectrometry (MS)-based approaches to facilitate the identification and quantification of proteins and their major post-translational modifications (PTMs) including phosphorylation, ubiquitylation and acetylation in the context of diseases. The Core has a wide breadth of expertise in discovery as well as targeted quantitative proteomics methods and strategies. This includes stable isotope labeling by amino acids in cell culture (SILAC) labeling, stable isotope labeling in mammals (SILAM), tandem mass tags (TMT) labeling, filter-aided sample preparation (FASP) based protein extraction and digestion, peptide fractionation methods such as basic reverse-phase liquid chromatography (bRPLC) and strong cation exchange (SCX), chemical and affinity-based PTM-enrichment methods, high-resolution high- accuracy mass spectrometry analysis for global proteomic profiling, targeted quantitation strategies including Multiple Reaction Monitoring (MRM), and bioinformatics and computational tools for the interpretation of even large-scale datasets. The combination of these high-end technologies offers powerful tools to address the proposed research questions of the JHM Udall Center. The overall goal of the Proteomics Core (Core D) is to use state-of-the-art mass spectrometry-based proteomics to facilitate the discovery and validation of protein molecules implicated in PD pathogenesis, providing support to all proposed basic science projects within this Udall Center and to the broader Morris K. Udall scientific community involved in PD research.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Hinkle, Jared T; Perepezko, Kate; Rosenthal, Liana S et al. (2017) Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord :
Panicker, Nikhil; Dawson, Valina L; Dawson, Ted M (2017) Activation mechanisms of the E3 ubiquitin ligase parkin. Biochem J 474:3075-3086
Dawson, Ted M; Dawson, Valina L (2017) Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annu Rev Pharmacol Toxicol 57:437-454
Yun, Seung Pil; Kim, Hyojung; Ham, Sangwoo et al. (2017) VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2. Cell Death Dis 8:e2741
Sulzer, David; Alcalay, Roy N; Garretti, Francesca et al. (2017) T cells from patients with Parkinson's disease recognize ?-synuclein peptides. Nature 546:656-661
Liddelow, Shane A; Guttenplan, Kevin A; Clarke, Laura E et al. (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481-487
Xiong, Yulan; Dawson, Ted M; Dawson, Valina L (2017) Models of LRRK2-Associated Parkinson's Disease. Adv Neurobiol 14:163-191
Gwinn, Katrina; David, Karen K; Swanson-Fischer, Christine et al. (2017) Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomark Med 11:451-473
Ando, Maya; Fiesel, Fabienne C; Hudec, Roman et al. (2017) The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol Neurodegener 12:32
Lee, Yunjong; Stevens, Daniel A; Kang, Sung-Ung et al. (2017) PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Rep 18:918-932

Showing the most recent 10 out of 228 publications